Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Alexza Pharmaceuticals: Forward Looking Approval Catalyst In PlayM. E. Garza • Wed, Dec 14, 2011 -
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Using Options To Benefit From The Binary Nature Of FDA DecisionsDavid Anber • Thu, Oct 18, 2012 -
-
-
-
4 Healthcare Stocks Breaking Out Mid-WeekTimeless Wealth • Thu, May 3, 2012 -
-
-
Alexza Pharmaceuticals Inc. - Special CallWed, May 8
-
Alexza Pharmaceuticals, Inc., Q3 2009 Earnings Call TranscriptMon, Nov 9, 2009
-
Alexza Pharmaceuticals, Inc. Q4 2008 Earnings Call TranscriptTue, Mar 10, 2009
-
Alexza Pharmaceuticals, Inc. Q3 2008 Earnings Call TranscriptTue, Nov 18, 2008
-
Alexza Pharmaceuticals, Inc. Q2 2008 Earnings Call TranscriptTue, Sep 2, 2008
-
Alexza Pharmaceuticals, Inc. Q1 2008 Earnings Call TranscriptMon, May 12, 2008
-
Alexza Pharmaceuticals, Inc.Q4 2007 Earnings Call TranscriptMon, Mar 17, 2008
-
PR Newswire (May 8, 2013)
-
PR Newswire (May 8, 2013)
-
PR Newswire (May 1, 2013)
-
PR Newswire (Apr 22, 2013)
-
PR Newswire (Mar 26, 2013)
-
PR Newswire (Mar 13, 2013)
-
PR Newswire (Mar 6, 2013)
-
PR Newswire (Feb 25, 2013)
-
PR Newswire (Feb 21, 2013)
-
PR Newswire (Jan 3, 2013)
-
at MarketWatch.com (Dec 24, 2012)
-
at MarketWatch.com (Dec 24, 2012)
-
at MarketWatch.com (Dec 21, 2012)
-
PR Newswire (Nov 6, 2012)
-
PR Newswire (Oct 18, 2012)
-
PR Newswire (Oct 17, 2012)
ALXA vs. ETF Alternatives
Company Description
We are a pharmaceutical company focused on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system, or CNS, conditions. All of our product candidates are based on our proprietary technology, the Staccato system. The... More
